The effect of Ginger consumption on inflammation and blood pressure in patients with type 2 diabetes mellitus

The effect of Ginger consumption on C-reactive protein, Tumor necrosis factor a, prostaglandin E2 and blood pressure in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204159472N1

Enrollment

Registered

2012-04-18

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetese melitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: control group :flour, 1600 milli grams(one 800 milligrams capsule before lunch and one before dinner) per day and during 3 months (12 weeks). Intervention 2: intervention group : Ginge

Placebo

Treatment - Drugs

control group :flour, 1600 milli grams(one 800 milligrams capsule before lunch and one before dinner) per day and during 3 months (12 weeks)

intervention group : Ginger supplement, 1600 mili gram(one 800 milligrams capsule before lunch and one before dinner) per day during 3 months(12 weeks)

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with type 2 diabetes; Diabetes duration of at least 1 years with 0ral medications; 30-70 years ages; Hb A1c :7-10% ; BMI between 20-35; not smoking and alcohol; not pregnancy and lactation. exclusion criteria: Patient unwillingness to continue with the plan; changes in type or dose of medication; Changes in diet or physical activity every day; taking less than 80% of supplements given to patients at baseline(the compaliance lower than %80); consumption of contraceptives,multivitamins and antioxidant supplements; renal , hepatic , thyroid, parathyroid diseases, cancer,inflammation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum CRP. Timepoint: before and after 3 month of intervention. Method of measurement: turbidometry.;Plasma PGE2. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;Serum TNF alfa. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;Systolic and diastolic blood pressure. Timepoint: before and after 3 month of intervention. Method of measurement: sphygmomanometer.	—

Measure

Time frame

Serum CRP. Timepoint: before and after 3 month of intervention. Method of measurement: turbidometry.;Plasma PGE2. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;Serum TNF alfa. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;Systolic and diastolic blood pressure. Timepoint: before and after 3 month of intervention. Method of measurement: sphygmomanometer.

—

Secondary

Measure	Time frame
FBS. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;Insulin. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;HbA1C. Timepoint: before and after 3 month of intervention. Method of measurement: Bronate Affinity.;HOMA-IR. Timepoint: before and after 3 month of intervention. Method of measurement: insulin × glucose / 22.5.;Choleserol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;TG. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;LDL cholesterol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;HDL cholesterol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;Waist circumference. Timepoint: before and after 3 month of intervention. Method of measurement: meter.	—

Measure

Time frame

FBS. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;Insulin. Timepoint: before and after 3 month of intervention. Method of measurement: ELISA.;HbA1C. Timepoint: before and after 3 month of intervention. Method of measurement: Bronate Affinity.;HOMA-IR. Timepoint: before and after 3 month of intervention. Method of measurement: insulin × glucose / 22.5.;Choleserol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;TG. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;LDL cholesterol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;HDL cholesterol. Timepoint: before and after 3 month of intervention. Method of measurement: colorimetry.;Waist circumference. Timepoint: before and after 3 month of intervention. Method of measurement: meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTahereh Arablou

Tehran University of Medical Sciences

t.arablou@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026